# synthesis of prodrug analogs and cyclopentane peptide nucleic acid (PNA) precursors

Canonical: https://abierto.us/opportunities/75n98026q00819creageninc

- Solicitation number: 75N98026Q00819CREAGENINC
- Notice type: Presolicitation
- Status: Closed. Deadline was July 5, 2026 at 9:00 AM EDT
- Department: Department of Health and Human Services
- Agency: National Institutes of Health
- Contracting office: National Institutes of Health Olao (75N980)
- NAICS: 325414 Biological Product (except Diagnostic) Manufacturing
- Product or service code: 6505 Drugs and Biologicals
- Place of performance: Bethesda, Maryland
- First posted: July 16, 2026
- Last posted: July 16, 2026
- SAM.gov: https://sam.gov/workspace/contract/opp/f91c144744ce480287dce66492d1ddf8/view

## Description

**Background Information:** The National Institute of Diabetes and Digestive and Kidney Diseases conducts and supports biomedical research to improve the understanding, prevention, and treatment of diseases affecting human health.? ? Within the Laboratory of Bioorganic Chemistry, the Synthetic Bioactive Molecules Section conducts research focused on the discovery and development of novel therapeutic compounds for the treatment and prevention of cancer and HIV infection.

Ongoing studies have?identified?several promising?sulfanylbenzamide-derived compounds and?cyclopentane peptide?nucleic acid precursor materials with potential?applications?as anti-cancer therapeutics, HIV prevention and treatment agents, and diagnostic technologies.? ? To support these research efforts, the Synthetic Bioactive Molecules Section?requires?synthesis scale-up, custom synthesis, purification, and characterization of optimized lead compounds and specialized precursor materials.

These materials are not commercially available and require specialized synthetic?expertise?and production capabilities to generate quantities sufficient for continued preclinical evaluation.? The materials produced under this requirement will be used in ongoing preclinical studies to evaluate compound activity,?optimize?lead candidates, and support advancement toward future clinical development.?

## Publications

- July 16, 2026: Presolicitation, due July 5, 2026 at 9:00 AM EDT. Notice f91c144744ce480287dce66492d1ddf8. https://sam.gov/workspace/contract/opp/f91c144744ce480287dce66492d1ddf8/view

## Points of contact

- Vishnuvajjala Hanumanth Rao, vishnuh@mail.nih.gov

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/75n98026q00819creageninc.